CN114680336A - Drop containing fructus cannabis unsaturated fatty acid and preparation method thereof - Google Patents
Drop containing fructus cannabis unsaturated fatty acid and preparation method thereof Download PDFInfo
- Publication number
- CN114680336A CN114680336A CN202011607775.7A CN202011607775A CN114680336A CN 114680336 A CN114680336 A CN 114680336A CN 202011607775 A CN202011607775 A CN 202011607775A CN 114680336 A CN114680336 A CN 114680336A
- Authority
- CN
- China
- Prior art keywords
- unsaturated fatty
- fructus cannabis
- fatty acid
- percent
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000021122 unsaturated fatty acids Nutrition 0.000 title claims abstract description 73
- 150000004670 unsaturated fatty acids Chemical class 0.000 title claims abstract description 73
- 238000002360 preparation method Methods 0.000 title abstract description 28
- 240000004308 marijuana Species 0.000 title 1
- 241000218236 Cannabis Species 0.000 claims abstract description 65
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 23
- 241000195493 Cryptophyta Species 0.000 claims abstract description 18
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 18
- 239000000796 flavoring agent Substances 0.000 claims abstract description 15
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 13
- 239000003921 oil Substances 0.000 claims description 36
- 235000019198 oils Nutrition 0.000 claims description 36
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 235000006708 antioxidants Nutrition 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000010460 hemp oil Substances 0.000 claims description 7
- 108700000434 Cannabis sativa edestin Proteins 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- 229940093503 ethyl maltol Drugs 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 14
- 206010039966 Senile dementia Diseases 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 235000016709 nutrition Nutrition 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 235000019197 fats Nutrition 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract 1
- 235000021081 unsaturated fats Nutrition 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 66
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 34
- 229940090949 docosahexaenoic acid Drugs 0.000 description 33
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 13
- 244000025254 Cannabis sativa Species 0.000 description 8
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 8
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 8
- 235000009120 camo Nutrition 0.000 description 8
- 235000005607 chanvre indien Nutrition 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000011487 hemp Substances 0.000 description 8
- 229960004488 linolenic acid Drugs 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 229940098462 oral drops Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
- A23D9/04—Working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/06—Preservation of finished products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a fructus cannabis unsaturated fatty acid-containing drop, which comprises DHA algae oil, fructus cannabis unsaturated fatty acid, soybean phospholipid, a flavoring agent and fructus cannabis oil. After the DHA algae oil, the fructus cannabis unsaturated fatty acid, the soybean phospholipid and the fructus cannabis oil are combined in a reasonable proportion, the nutrition component proportion is reasonable, the bioavailability of each nutrition component is high, the in-vivo bioavailability of the DHA can be particularly obviously improved, and the DHA-containing health food has various effects of assisting in enhancing memory, preventing senile dementia, reducing blood fat and the like. The fructus cannabis-containing unsaturated fat drop is simple in preparation method, stable in product and capable of being stored for a long time.
Description
Technical Field
The invention relates to the field of food, and in particular relates to a drop containing fructus cannabis unsaturated fatty acid and a preparation method thereof.
Background
With the social progress, the improvement of the living standard of people and the improvement of medical insurance, the average life of the population in China is obviously prolonged at present, and the proportion of the old people to the general population is continuously increased. The huge population of the old people needs to pay close attention to the health of the old people and improve the self-health care and disease prevention capability of the old people. Scientific research shows that after the age of 60, the aging speed of brain cells begins to be accelerated, the memory is reduced, and the incidence rate of Alzheimer disease (senile dementia) is increased. The symptoms of the senile dementia patients are represented by cognitive function impairment and mental abnormality, and the final life cannot be managed by oneself, so that the life quality of the patients is seriously influenced, and the family and the society of the patients are also heavily burdened. The senile dementia can not be cured so far, the conventional medicines on the market can only relieve the symptoms of the senile dementia at present, the medicine effect is very short, and the development of the disease can not be controlled. At present, no medicine can permanently stop the brain atrophy of a patient, so that the development of a food capable of slowing down the memory decline of the elderly, improving the memory of the elderly and preventing the senile dementia has very important significance.
Hemp seed is a very good oil processing material as well as a food material. The Omega-3 unsaturated fatty acids in fructus Cannabis are a group of polyunsaturated fatty acids, and are helpful for nourishing brain, improving intelligence, keeping blood vessel smooth, and preventing cardiovascular and cerebrovascular diseases such as thrombosis or blood lipid, wherein the alpha-linolenic acid can be converted into docosahexaenoic acid (DHA) for maintaining cranial nerve operation in human body, and provide sufficient nutrition for brain. The lack of alpha-linolenic acid in the human body easily causes insufficient intake of Omega-3 unsaturated fatty acid to cause encephalatrophy, and for the elderly, the lack of alpha-linolenic acid can increase the occurrence probability of senile dementia.
The administration of Omega-3 enhances learning, memory and concentration. Since Omega-3 unsaturated fatty acids are not self-synthesized in the body, Omega-3 unsaturated fatty acids can be ingested only from food, whereas Omega-3 unsaturated fatty acids contained in daily foods in small amounts do not satisfy the needs of the human body, and thus it is necessary to improve the health condition of the human body by supplementing such essential unsaturated fatty acids through external ingestion.
At present, commercially available products rich in Omega-3 unsaturated fatty acids mainly appear in the form of capsules, such as DHA soft capsules, fish oil soft capsules, krill oil capsules and the like, however, the storage period of the existing products is not long, the oil loading amount in the capsules is not large, the oil rich in Omega-3 unsaturated fatty acids is poor in solubility, is not easy to absorb by a human body, and has low bioavailability, so that the product performance is influenced.
Therefore, there is a need to develop an unsaturated fatty acid product with long shelf life and high bioavailability.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide the fructus cannabis unsaturated fatty acid-containing drop which has the advantages of reasonable ratio of all nutrient components, high in vivo bioavailability, stable quality and long storage period, and has various effects of assisting in enhancing memory, preventing senile dementia, reducing blood fat and the like; the invention also aims to provide a preparation method of the drop, which has the advantages of simple operation and suitability for large-scale production.
In one aspect, the invention provides a drop containing fructus cannabis unsaturated fatty acid, which comprises the following components in percentage by mass:
DHA algal oil: 5 to 25 percent;
fructus cannabis unsaturated fatty acids: 5 to 65 percent;
soybean lecithin: 3 to 15 percent;
flavoring agent: 0.1 to 0.8 percent;
hemp seed oil: and (4) the balance.
In a preferred embodiment, the drops containing edestin unsaturated fatty acids according to the invention comprise the following components in mass percent:
DHA algal oil: 10 to 20 percent;
fructus cannabis unsaturated fatty acids: 10 to 60 percent;
soybean lecithin: 5 to 10 percent;
flavoring agent: 0.3 to 0.5 percent;
hemp seed oil: and (4) the balance.
The DHA algae oil is a general name of all oil substances in algae, is a slightly fishy faint yellow liquid at normal temperature, and has the main effective components of EPA, DHA and the like. DHA is an indispensable material basis for brain cell development and exercise. The level of DHA in vivo directly affects the proliferation of brain cells, nerve conduction, and the growth and development of synapses. Human memory and mental function are maintained and enhanced by DHA. The DHA supplement can promote brain cell full development, delay intelligence decline and amnesia, and prevent Alzheimer disease.
The fructus cannabis unsaturated fatty acid is high-grade health edible oil, the content of the unsaturated fatty acid is more than or equal to 92 percent, the omega-6 of linoleic acid is more than or equal to 56 percent, the omega-3 of linolenic acid is more than or equal to 14 percent, and the fructus cannabis unsaturated fatty acid is rich in natural VA, VD and other nutrient substances. The fructus cannabis unsaturated fatty acid has the effects of strengthening brain and nourishing brain, the fructus cannabis unsaturated fatty acid does not contain cholesterol, the senile dementia can be effectively prevented, and abundant linoleic acid and linolenic acid can remove impurities metabolized in blood vessels, purify blood and provide fresh blood for brain. Alpha-linolenic acid is a polyunsaturated fatty acid with three double bonds, is an omega-3 essential fatty acid, is used for improving intelligence, resisting thrombus, protecting liver and the like, and is one of essential nutrients for people.
The soybean phospholipid is obtained by introducing unsaturated fatty acids such as medium carbon chain grease, conjugated linoleic acid, vegetable catalpol or n-3 series polyunsaturated fatty acids and the like into phospholipid molecules through ester exchange reaction, not only maintains good emulsification property of the phospholipid, but also greatly improves the nutritional value of the phospholipid, and has better absorption promoting effect when being matched with DHA algal oil and fructus cannabis unsaturated fatty acids. The soybean lecithin is similar to a key or a carrier of a blood brain barrier, carries nutrient components such as DHA in DHA algae oil and linolenic acid omega-3 in fructus cannabis unsaturated fatty acid, enters the brain through the blood brain barrier, supplements nutrition for the brain of a human body, improves memory and prevents senile dementia.
The nutrient substances in the drop containing the fructus cannabis unsaturated fatty acid are reasonable in proportion and meet the international requirements. The above nutritional ingredients are reasonably matched, and the product has effects of improving memory, preventing senile dementia, reducing blood lipid, etc.
In a preferred embodiment, in said drops containing cannabis unsaturated fatty acids, said flavouring agent is a mixture consisting of ethyl maltol and a food flavour, wherein the mass ratio of ethyl maltol to food flavour is 2: 3.
The ethyl maltol and the food essence in the fructus cannabis unsaturated fatty acid-containing drop are diffused into the mouth, so that the bad smell of the raw material components in the drop is completely covered, and the drop is easier to eat.
In a preferred embodiment, said drops containing edestin fatty acids further comprise an antioxidant in a quantity comprised between 0.1% and 1.5% by mass, preferably between 0.5% and 1% by mass.
In a preferred embodiment, in said drops containing edestin fatty acids, the antioxidant may be vitamin C, vitamin E or a combination thereof.
In a preferred embodiment, the drops containing unsaturated fatty acids of fructus cannabis according to the invention have a particle size of 350-500nm, preferably 400-450 nm.
The drop is a liquid preparation, is a heterogeneous liquid dispersion system formed by mutually dispersing multiple phases, and has the particle size of 350-500nm, preferably 400-450nm, so that the drop is more stable and has longer shelf life.
In yet another aspect, the present invention provides a method for preparing drops containing hemp seed unsaturated fatty acid, comprising the steps of:
1) uniformly mixing DHA algae oil, fructus Cannabis unsaturated fatty acid, soybean phospholipid, correctant and fructus Cannabis oil to obtain mixed solution;
2) introducing nitrogen into the prepared mixed solution for protection, and discharging at the temperature of 20 ℃;
3) sterilizing, vacuum defoaming, and packaging to obtain drop containing fructus Cannabis unsaturated fatty acid.
In a preferred embodiment, in the method for the preparation of drops containing edestin unsaturated fatty acids according to the invention, an antioxidant is also added in step 2), wherein the antioxidant may be vitamin C, vitamin E or a combination thereof.
The invention adopts a step-by-step mixing mode, and the raw materials are sequentially and gradually added into a mixing system to be fully dispersed, the obtained drop is stable in dispersion, the stability is improved under the protection of nitrogen gas, and the storage period is prolonged.
In conclusion, compared with the prior art, the fructus cannabis unsaturated fatty acid-containing drops and the preparation method thereof have the following beneficial effects:
(1) after the DHA algae oil, the fructus cannabis unsaturated fatty acid, the soybean lecithin and the fructus cannabis oil are combined in a reasonable proportion, the drop containing the fructus cannabis unsaturated fatty acid is reasonable in proportion of nutritional ingredients and high in bioavailability of the nutritional ingredients, can especially remarkably improve the bioavailability of the DHA in vivo, and has various effects of assisting in enhancing memory, preventing senile dementia, reducing blood fat and the like; the drop adopts a nitrogen gas protection mode, and the particle size of the drop is 350-500nm, preferably 400-450nm, so that the drop is more stable, the shelf life is longer and can be prolonged to 2 years, and therefore, the drop containing the hemp seed unsaturated fatty acid has the advantage of long storage period.
(2) The preparation method of the drop has the advantages of simple operation and suitability for large-scale production.
Detailed Description
For a better understanding of the present invention, the following examples are set forth to illustrate, but are not to be construed as the limit of the present invention.
Hereinafter, the reagents used in the examples of the present invention are all conventional in the art, if not specifically described. The corrigent is a mixture of ethyl maltol and food essence according to the mass ratio of 2: 3. The selected DHA algae oil is a raw material with DHA content of 75%, and the fructus Cannabis unsaturated fatty acid is a raw material with alpha-linolenic acid content of 55%.
Example 1: preparation of drops containing fructus Cannabis unsaturated fatty acid
The components and the corresponding mass percentages thereof are shown in table 1 and are prepared by the following steps:
1) uniformly mixing DHA algae oil, fructus Cannabis unsaturated fatty acid, soybean phospholipid, correctant and fructus Cannabis oil to obtain mixed solution;
2) introducing nitrogen into the prepared mixed solution for protection, and discharging at the temperature of 20 ℃;
3) sterilizing, vacuum defoaming, and packaging to obtain drop containing fructus Cannabis unsaturated fatty acid.
Example 2 to example 6: preparation of drops containing fructus Cannabis unsaturated fatty acid
Drops containing hemp seed unsaturated fatty acid were prepared according to the same procedure as in example 1, with the mass percentages of the components in examples 2 to 6 in table 1.
Table 1 components and mass percentages thereof in examples 1 to 6 (total mass 100g)
Example 7: preparation of drops containing fructus Cannabis unsaturated fatty acid
The components and their contents were the same as in example 1, except that they were prepared by the following steps:
1) uniformly mixing DHA algae oil, fructus Cannabis unsaturated fatty acid, soybean phospholipid, correctant and fructus Cannabis oil to obtain mixed solution;
2) discharging the prepared mixed solution at 20 ℃;
3) sterilizing, and packaging to obtain drop containing fructus Cannabis unsaturated fatty acid.
Example 8: preparation of drop containing fructus Cannabis unsaturated fatty acid
The DHA algae oil, fructus cannabis unsaturated fatty acid, soybean phospholipid and flavoring agent have the same mass percentage content as that in example 1, and are different from example 1 in that the soybean phospholipid and flavoring agent also contain 0.1 mass percentage of antioxidant vitamin C, and the balance is fructus cannabis oil. The preparation method comprises the following steps:
1) uniformly mixing DHA algae oil, fructus Cannabis unsaturated fatty acid, soybean phospholipid, correctant and fructus Cannabis oil to obtain mixed solution;
2) adding an antioxidant into the prepared mixed solution, uniformly mixing, introducing nitrogen for protection, and discharging at the temperature of 20 ℃;
3) sterilizing, vacuum defoaming, and packaging to obtain drop containing fructus Cannabis unsaturated fatty acid.
Example 9: preparation of drops containing fructus Cannabis unsaturated fatty acid
The DHA algae oil, fructus cannabis unsaturated fatty acid, soybean phospholipid and flavoring agent have the same mass percentage content as that in example 1, and are different from that in example 1 in that the DHA algae oil, fructus cannabis unsaturated fatty acid, soybean phospholipid and flavoring agent also contain 1 mass percentage of antioxidant vitamin E, and the balance is fructus cannabis oil. The preparation method is the same as example 8.
Example 10: preparation of drop containing fructus Cannabis unsaturated fatty acid
The DHA algae oil, fructus cannabis unsaturated fatty acid, soybean phospholipid and flavoring agent are the same as those in example 1 in mass percentage, and the DHA algae oil, fructus cannabis unsaturated fatty acid, soybean phospholipid and flavoring agent are different from those in example 1 in that the DHA algae oil, fructus cannabis unsaturated fatty acid, soybean phospholipid and flavoring agent also contain 0.5% of antioxidant in mass percentage, the antioxidant is a mixture of vitamin C and vitamin E according to the mass ratio of 1:1, and the balance is fructus cannabis oil. The preparation method is the same as example 8.
In comparative examples 1 to 3 below, the content of the substitute component was the same as that of the component substituted in example 1, and the other components and their contents were the same as in example 1.
Comparative example 1: preparation of oral drops
The preparation was carried out according to the same procedure as in example 1, except that monoglyceride was used instead of soybean phospholipid in example 1, as in example 1.
Comparative example 2: preparation of oral drops
The preparation was carried out according to the same procedure as in example 1, except that olive oil was used instead of the hemp seed oil in example 1 from example 1.
Comparative example 3: preparation of oral drops
The preparation was carried out according to the same procedure as in example 1, except that olive oil was used instead of the hemp seed unsaturated fatty acid in example 1 from example 1.
Comparative example 4: preparation of oral drops
The preparation was carried out in the same manner as in example 1, except that the unsaturated fatty acid content of hemp seed was 70%, the DHA algal oil, soybean phospholipids and taste-masking agent were added in the same manner as in example 1, and the balance was supplemented with hemp seed oil, as in example 1.
Comparative example 5: preparation of oral drops
The preparation was carried out according to the same procedure as in example 1, except that the DHA algal oil was added in an amount of 30%, the hemp seed unsaturated fatty acid, soybean phospholipid, and taste modifier were added in the same amounts as in example 1, and the balance was supplemented with hemp seed oil.
Examples of the experiments
And (3) bioavailability test:
male Wistar rats (provided by the Experimental animal center of the department of medicine of Beijing university) with a weight of 260-. Rats were intragastrically perfused with the drops of examples 1-10 and comparative examples 1-6, respectively, and after administration for 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h, orbital venous plexus blood was collected at 0.5mL in heparinized tubes, incubated with an oil bath of hemp at 37 ℃ for 30min, then centrifuged at 5000r/min for 10min, plasma was separated and the supernatant was collected and stored at-20 ℃ for determination of drug concentration. The data from the DHA blood concentration-time curve measurements were calculated by DAS pharmacokinetics and are shown in table 2 below.
TABLE 2 DHA bioavailability test results
As can be seen from the test data in table 2, the interaction between the components in the drops, the replacement of the components and the variation of the distribution ratio of the components all have an effect on the absorption of the components. The application protects that the DHA bioavailability of the drops with the specific proportioning components is improved. Specifically, the bioavailability of DHA in drops by rats in examples 1-10 was significantly higher than that of drops by rats in comparative examples 1-5, and especially the bioavailability of DHA was the highest in the best examples 9-10.
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments, and all technical solutions belonging to the idea of the present invention belong to the protection scope of the present invention. It should be noted that modifications and embellishments within the scope of the invention may occur to those skilled in the art without departing from the principle of the invention, and are considered to be within the scope of the invention.
Claims (8)
1. A drop containing fructus cannabis unsaturated fatty acid comprises the following components in percentage by mass:
DHA algal oil: 5 to 25 percent;
fructus cannabis unsaturated fatty acids: 5 to 65 percent;
soybean lecithin: 3 to 15 percent;
flavoring agent: 0.1 to 0.8 percent;
hemp seed oil: and (4) the balance.
2. A drop containing fructus cannabis unsaturated fatty acid as claimed in claim 1, comprising the following components in mass percent:
DHA algal oil: 10 to 20 percent;
fructus cannabis unsaturated fatty acids: 10 to 60 percent;
soybean lecithin: 5 to 10 percent;
flavoring agent: 0.3 to 0.5 percent;
hemp seed oil: and (4) the balance.
3. Drops containing edestin fatty acids according to claim 1 or 2, wherein the flavouring is a mixture of ethyl maltol and food essence, wherein the mass ratio of ethyl maltol to food essence is 2: 3.
4. Drops containing edestin fatty acids according to claim 1 or 2, wherein they further comprise an antioxidant in a percentage by mass ranging from 0.1% to 1.5%, preferably from 0.5% to 1%.
5. Drops containing edestan unsaturated fatty acids according to claim 4, wherein said antioxidant is vitamin C, vitamin E or a combination thereof.
6. Drops containing fructus cannabis unsaturated fatty acid according to claim 1 or 2, wherein the particle size of the drops containing fructus cannabis unsaturated fatty acid is 350-500nm, preferably 400-450 nm.
7. A method for preparing drop containing fructus Cannabis unsaturated fatty acid comprises the following steps:
1) uniformly mixing DHA algae oil, fructus Cannabis unsaturated fatty acid, soybean phospholipid, correctant and fructus Cannabis oil to obtain mixed solution;
2) introducing nitrogen into the prepared mixed solution for protection, and discharging at the temperature of 20 ℃;
3) sterilizing, vacuum defoaming, and packaging to obtain drop containing fructus Cannabis unsaturated fatty acid.
8. The method according to claim 7, wherein an antioxidant is further added in step 2), wherein the antioxidant is vitamin C, vitamin E or a combination thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011607775.7A CN114680336A (en) | 2020-12-30 | 2020-12-30 | Drop containing fructus cannabis unsaturated fatty acid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011607775.7A CN114680336A (en) | 2020-12-30 | 2020-12-30 | Drop containing fructus cannabis unsaturated fatty acid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114680336A true CN114680336A (en) | 2022-07-01 |
Family
ID=82132809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011607775.7A Pending CN114680336A (en) | 2020-12-30 | 2020-12-30 | Drop containing fructus cannabis unsaturated fatty acid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114680336A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679593A (en) * | 2005-02-04 | 2005-10-12 | 海南国栋药物研究所有限公司 | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E |
| US20070032548A1 (en) * | 2005-07-08 | 2007-02-08 | Ellis Lorie A | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| CN105343184A (en) * | 2015-12-01 | 2016-02-24 | 无限极（中国）有限公司 | Composition and application thereof |
| CN106729280A (en) * | 2016-12-27 | 2017-05-31 | 南京圣诺生物科技实业有限公司 | A kind of composition containing phosphatidylserine and its preparation method and application |
| CN111743996A (en) * | 2020-06-24 | 2020-10-09 | 上海互众药业有限公司 | Oral emulsion for improving memory and senile dementia and preparation method thereof |
-
2020
- 2020-12-30 CN CN202011607775.7A patent/CN114680336A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679593A (en) * | 2005-02-04 | 2005-10-12 | 海南国栋药物研究所有限公司 | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E |
| US20070032548A1 (en) * | 2005-07-08 | 2007-02-08 | Ellis Lorie A | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| CN105343184A (en) * | 2015-12-01 | 2016-02-24 | 无限极（中国）有限公司 | Composition and application thereof |
| CN106729280A (en) * | 2016-12-27 | 2017-05-31 | 南京圣诺生物科技实业有限公司 | A kind of composition containing phosphatidylserine and its preparation method and application |
| CN111743996A (en) * | 2020-06-24 | 2020-10-09 | 上海互众药业有限公司 | Oral emulsion for improving memory and senile dementia and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 萧闵 等: "火麻仁油与藻油混合物对营养肥胖大鼠的降脂减肥作用研究", 《湖北中医药大学学报》, vol. 18, no. 4, pages 12 - 15 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2093996C1 (en) | Method of addition to child's nutrient mixture of docosahexanoic and arachidonic acids (versions) and composition (versions) | |
| AU666246B2 (en) | Nutritional product for persons having a neurological injury | |
| US8075910B2 (en) | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions | |
| CN103891924B (en) | A kind of ready-mixed oil containing corn oil and preparation method thereof | |
| CN108402188A (en) | A kind of edible oil and preparation method for strengthening supplement DHA and alpha-linolenic acid | |
| JP2004501937A (en) | Vitamin K and essential fatty acids | |
| CN108720021A (en) | DHA algal oil microscapsule powder and preparation method thereof | |
| CN103190619A (en) | Fish oil and linseed oil soft capsules and preparation method thereof | |
| EP2520177B2 (en) | Nutritional compositions comprising fruit flakes containing docosahexaenoic acid | |
| CN112273651A (en) | Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof | |
| CN109123660A (en) | A kind of walnut lactalbumin composite powder and preparation method thereof for maternal nutritional product | |
| AU639675B2 (en) | Triglyceride, nutritional composition comprising such triglyceride, and use of the nutritional composition for nutrition | |
| CN111567632A (en) | Dietary fatty acid nutrition balance blend oil and preparation method thereof | |
| CN102578307A (en) | Dual-sub-acid high-end vegetable oil and preparation method thereof | |
| CN102106411B (en) | Nutrient oil for diabetics | |
| CN111743996A (en) | Oral emulsion for improving memory and senile dementia and preparation method thereof | |
| JPH0127A (en) | Drugs that act on the heart and cardiovascular system and methods for their production | |
| US20120184760A1 (en) | Removal of monoglycerides from fatty acid concentrates | |
| CN114680336A (en) | Drop containing fructus cannabis unsaturated fatty acid and preparation method thereof | |
| CN113575698B (en) | Fish oil soft capsule and preparation method and application thereof | |
| CN1679593A (en) | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E | |
| CN109152403A (en) | Composition comprising marine oil and juice is used to improve the purposes of muscle performance | |
| CN107114491A (en) | The elderly's tea oil and its production method | |
| CN115315198A (en) | Composition for improving friendliness and/or co-emotion | |
| JPS6115648A (en) | Oil and fat food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |